A receptor is a protein on the surface of a cell that waits for a specific signal. When the right molecule arrives and binds, the cell does something: releases a hormone, changes its metabolism, sends a nerve impulse. An agonist is a molecule that binds and switches the receptor on. Retatrutide is an agonist at three of them. This article is about what those three do.
GLP-1: the one everything started with
Glucagon-like peptide-1 is a hormone made in the gut and released within minutes of eating. It has several jobs, and they all point the same way. It tells the pancreas to release insulin, but only when glucose is high, which is why it does not cause hypoglycaemia the way injected insulin can. It slows the emptying of the stomach. And it acts on the brain to reduce appetite and the reward value of food.
The natural hormone lasts about two minutes in the blood before an enzyme destroys it. The whole history of the drug class is the history of making a GLP-1 that lasts longer: exenatide for hours, liraglutide for a day, semaglutide for a week3.
GIP: the one that was supposed to be useless
Glucose-dependent insulinotropic polypeptide is the other incretin. It too is released after a meal and too stimulates insulin. For decades it was considered a dead end for drug development because, in people with type 2 diabetes, the GIP response appeared blunted; the hormone was there, but the pancreas seemed to have stopped listening.
The turn came when a molecule engaging both GIP and GLP-1 receptors, tirzepatide, outperformed GLP-1 alone in head-to-head trials2. Why GIP agonism helps when GIP itself seems not to is still argued. The leading explanations involve effects in fat tissue and in the brain rather than the pancreas. What is not argued is the result.
Glucagon: the one that looked like a mistake
Glucagon is the hormone that raises blood glucose. It is released when glucose falls, and it tells the liver to break down stored glycogen and release sugar. Diabetes drugs have historically tried to block it.
Putting a glucagon agonist into a metabolic drug therefore looks backwards. The rationale is that glucagon receptor activation does something else as well: it increases energy expenditure, the rate at which the body burns calories at rest, and it drives fat breakdown in the liver. If the glucose-raising effect can be cancelled by enough GLP-1-driven insulin, what is left is a second route to weight loss that works on the output side of the energy equation rather than the intake side1.
That is the bet retatrutide makes. In the discovery work the compound was deliberately tuned with relatively greater activity at the GIP receptor and comparable activity at the other two1. The ratio is a design choice; a different ratio would be a different drug.
1 = engaged, 0 = not engaged
Lau 2015 [3], Coskun 2018 [2], Coskun 2022 [1]. Chart by TrueLab Care.
Why three is harder than two
Each receptor brings its own side-effect profile. GLP-1 brings nausea. GIP is relatively quiet. Glucagon brings a rise in heart rate and an open question about long-term cardiovascular effects. A triple agonist has to find a dose at which the combined benefit outruns the combined cost, and the trial data suggest that window narrows at the top end: the gap in weight loss between 9 mg and 12 mg is small, while adverse events keep climbing.
More receptors, in other words, is not a free upgrade. It is a more complicated molecule with a more complicated trade-off, and whether the trade is worth it is what the phase 3 programme exists to decide.
A note on the names
The three receptors have standard abbreviations: GLP-1R, GIPR and GCGR. A compound described as a "GLP-1 agonist" engages the first. A "dual agonist" or "GIP/GLP-1" engages the first two. "Triple agonist", "triple G" or "GGG" means all three. The nicknames are accurate; the mechanism behind them is what the rest of this series explains.